340B

Manufacturer updates

340B timline


February 1, 2022

AbbVie

Effective February 1, 2022, AbbVie will only provide 340B priced product to a single Contract Pharmacy if Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.
 
Contact: 

January 3rd, 2022

Amgen

Effective January 3rd, 2022, Amgen will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Policy is limited to four drugs and doesn’t include Federal Grantees.

Contact: 

support@340Besp.com

January 1st, 2021

Amgen 

Effective January 1st, 2021, Amgen will no longer provide voluntary, “340B like” discounts, on orphan designated drugs to participating Covered Entities.

Contact:
340Brelations@amgen.com

AstraZeneca

Effective October 1st, 2020, AstraZeneca will only provide 340B priced product to a single Contract Pharmacy.



Contact: membership@AstraZeneca.com 

Boehringer Ingelheim

Effective December 1, 2021, BI will add its specialty product, OFEV, to the list of products subject to its 340B Contract Pharmacy policy. BI restrictions from August 1, 2021, remain effective. Link to both notices below. 

Contact:
support@340Besp.com

Clovis

At this time, Clovis won’t be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovis’ products remain available through all historically available channels.

Contact:
priceadmin@clovisoncology.com

December 10th, 2021

Eli Lilly

Lilly announced on December 10th, 2021, an expansion to their contract pharmacy policy allowing 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform for dispenses on or after October 29th, 2021.

Contact:
340B@lilly.com

September 1st, 2020

Eli Lilly

Effective September 1st, 2020, Lilly restricted access for 340B priced product to Contract Pharmacies, except insulin.


Contact:
340B@lilly.com

Janssen

Effective January 1st, 2022, Janssen will no longer offer voluntary 340B pricing on orphan drugs to Covered Entities subject to the 340B orphan drug exclusion. This change will not impact separate agreements with impacted Covered Entities.

Merck

Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations. 

Contact:
340Bdata@merck.com

Novartis

Effective November 16th, 2020, Novartis will restrict 340B priced product to Contract Pharmacies based on a 40 mile radius for hospital Covered Entities. Federal Grantees not subject to limitations.

Contact: Novartis.340B@novartis.com

Novo Nordisk

Effective January 1st, 2021, Novo Nordisk will restrict 340B priced product to Contract Pharmacies for hospital Covered Entities. Federal Grantees not subject to limitations.


Contact: 340BInfo@novonordisk.com 

Sanofi

Effective March 1st, 2021, Sanofi will only provide 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform. 


Contact: Sanofi340Boperations@sanofi.com
 

UCB

Effective December 13th, 2021, UCB will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.

Contact:
support@340Besp.com

United Therapeutics

Effective December 1, 2021, United Therapeutics will only provide 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform. 

Contact:
340B@unither.com